Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series

Figures & data

Table 1 Baseline characteristics

	All eyes (n=62)	BRVO (n=40)	CRVO (n=22)
Age, years
Mean (SD)	72 (12.9)	74.6 (12)	67.4 (13.5)
Range	38–98	48–98	38–93
Sex, n (%)
Female	43 (68.3)	27 (67.5)	16 (72.7)
Male	19 (31.7)	13 (32.5)	6 (27.3)
Ethnicity, n (%)
Caucasian	32 (52.5)	22 (55)	11 (47.6)
African-American	5 (8.2)	1 (2.5)	4 (19)
Hispanic	24 (39.3)	17 (42.5)	7 (33)
Mean BCVA (letters)	47	54	42
Mean CFT, μm	470	445	516

Abbreviations: BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; BCVA, best-corrected visual acuity; SD, standard deviation; CFT, central foveal thickness.

Figure 1 Mean time to retreatment for each treatment cycle. Error bars represent 95% confidence intervals.

Abbreviations: BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion.

Figure 2 Mean peak change from baseline in best-corrected visual acuity (BCVA) in each treatment cycle.

Notes: (A) BCVA; (B) central retinal vein occlusion. Error bars represent 95% confidence intervals.

Figure 3 Percentage of patients achieving three or more lines of improvement in best-corrected visual acuity in each treatment cycle.

Notes: (A) Branch retinal vein occlusion; (B) central retinal vein occlusion.

Figure 4 Mean peak change from baseline in central foveal thickness (CFT).

Notes: (A) Branch retinal vein occlusion; (B) central retinal vein occlusion. Error bars represent 95% confidence intervals.

Figure 5 Percentage of patients with central foveal thickness ≤300 μm at any time in each treatment cycle.

Notes: (A) Branch retinal vein occlusion; (B) central retinal vein occlusion.